Grants for Special district governments - Consumer Protection

This funding opportunity provides $1 million to various organizations to develop and implement strategies for effectively sharing clinical practice guidelines, particularly in underserved communities, to improve healthcare quality and equity.

This funding opportunity is designed to support collaborations between the FDA and the generic drug industry to advance research and development of complex generic medications, ultimately improving patient access to safe and effective drugs.

This funding opportunity provides financial support to state and local governments, tribal entities, and accredited educational institutions to enhance their food testing laboratories' capabilities and improve national food safety through advanced testing and emergency response initiatives.

This funding opportunity provides financial support to various organizations, including universities and non-profits, to improve veterinary diagnostic capabilities and address public health issues related to animal food safety and antimicrobial resistance.

This funding opportunity supports a variety of organizations in conducting innovative research to develop medical products for preventing, diagnosing, and treating ALS and other rare neurodegenerative diseases.

This funding opportunity provides up to $1 million for various organizations to develop innovative projects that improve diversity and inclusivity in clinical trials, enhance data on underrepresented groups, and capture diverse patient perspectives to promote health equity.

This funding opportunity provides $250,000 to various organizations to develop educational programs that raise awareness about the health risks of skin lightening products and promote safer alternatives in communities.

This funding opportunity provides financial support for clinical trials aimed at developing new treatments for rare neurodegenerative diseases, targeting a wide range of eligible applicants including universities, nonprofits, and government entities.

This grant provides funding to various organizations, including governments and educational institutions, to promote research and initiatives that improve health equity for racial and ethnic minority populations.

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity provides $2 million to a variety of organizations for research projects focused on improving pain management, anesthesia safety, and addiction treatment strategies.

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs.Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants.The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516.FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

The Specialty Crop Assistance program, administered by the Florida Department of Agriculture and Consumer Services (FDACS), provides assistance for eligible expenses related to COVID-19 that benefit the production and distribution of Florida specialty crops. Eligible expenses include Personal Protection Equipment (PPE) and facility adjustments for worker and product safety. The program is open to specialty crop growers, processors, and distributors. Funding is provided through the Specialty Crop Block Grant Program, with a minimum reimbursement of $565.00 and a maximum reimbursement of $300,000.00 over the life of the project. The program has a total fund availability of $2,735,124.99, and applications will be processed on a first come first served basis until funds are depleted. The last day to apply for assistance is September 1, 2025. To apply, organizations must register as a state vendor at www.myfloridamarketplace.com, provide a substitute W9 form to the Florida Department of Financial Services, register or login to the FDACS online portal, complete and upload the HR133 Assistance program application to the FDACS online portal, and upload proof of purchase such as invoices marked 'paid', cancelled checks, or other substantial documentation of costs to be reimbursed. Eligible items for reimbursement include various PPE items and facility adjustments for worker and product safety. For additional questions, applicants can contact Kimberly Murphy at (850) 617-7397 or email [email protected].

The Pool Safely Grant Program funding opportunity assists states, local governments, and Native American Tribal Governments in implementing enforcement and education programs to prevent the drowning and drain entrapment of children in pools and spas.

AmeriCorps improves lives, strengthens communities, and fosters civic engagement through service and volunteering. AmeriCorps brings people together to tackle some of the countrys most pressing challenges through national service and volunteerism. AmeriCorps members and AmeriCorps Seniors volunteers serve with organizations dedicated to the improvement of communities and those serving. AmeriCorps helps make service a cornerstone of our national culture. This funding announcement is an opportunity for communities to apply for funding to engage adults ages 55 and older in tackling the communitys most pressing needs through the AmeriCorps Seniors RSVP program. This is an open competition across all states and territories.

This funding opportunity supports U.S.-based organizations in conducting research to better understand and manage heart-related side effects of cancer treatments, with a focus on improving detection, monitoring, and data sharing.

The purpose of this FOA is to develop and maintain Rapid Response Teams (RRTs) to facilitate long-term improvements and innovation to the national integrated food safety system by unifying and coordinating federal/state/local human and animal food (HAF) emergency response efforts including:1) Strengthening the link among epidemiology, lab and environmental health/regulatory components;2) Improving States' regulatory and surveillance HAF protection programs to include using Incident Command System (ICS)/National Incident Management System (NIMS) principles and a Unified Command structure to conduct integrated responses to all-hazards HAF emergencies, rapidly identifying and removing tainted food from commerce, and conducting root cause investigations to inform future prevention efforts; and3) Addressing supporting components, such as training, data sharing, data analysis, communications, continuous process improvement, and development of best practices and other resources to support national response capacity/capability development.

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.